Kikuchi Y, Kizawa I, Koyama E, Kato K
Obstet Gynecol. 1984 Apr;63(4):561-6.
A comparison of preoperative serum tumor markers (lactate dehydrogenase, lactate dehydrogenase isoenzymes, alpha-hydroxybutyrate dehydrogenase, alkaline phosphatase, aldolase, leucine aminopeptidase, cholinesterase, erythrocyte sedimentation reaction, carcinoembryonic antigen, alpha-fetoprotein, and beta 2-microglobulin) was made in 76 patients with ovarian or uterine cancer. Sixty-six patients with benign ovarian tumor served as control subjects. From analysis of each tumor marker the greatest positive results were obtained with the markers beta 2-microglobulin (57.1%), lactate dehydrogenase (53.1%), and hydroxybutyrate dehydrogenase (46.2%) for patients with carcinoma of the ovary. The use of these marker combinations in all ovarian cancer patients resulted in a marked increase of the positive rate from 57.1 to 85.2%. In stage I cases, the positive rate increased from 40.6 to 63.6%.
对76例卵巢癌或子宫癌患者的术前血清肿瘤标志物(乳酸脱氢酶、乳酸脱氢酶同工酶、α-羟丁酸脱氢酶、碱性磷酸酶、醛缩酶、亮氨酸氨肽酶、胆碱酯酶、红细胞沉降反应、癌胚抗原、甲胎蛋白和β2-微球蛋白)进行了比较。66例良性卵巢肿瘤患者作为对照。通过对每种肿瘤标志物的分析,卵巢癌患者中β2-微球蛋白(57.1%)、乳酸脱氢酶(53.1%)和羟丁酸脱氢酶(46.2%)的阳性结果最为显著。在所有卵巢癌患者中使用这些标志物组合,阳性率从57.1%显著提高到85.2%。在I期病例中,阳性率从40.6%提高到63.6%。